Lecanemab: the drug giving hope to people at risk of dementia | HMRI
Lecanemab, a drug trialed at HMRI, effectively removes amyloid from the brain, potentially preventing Alzheimer's and dementia. The trial involved 400 participants nationwide, with 20 found to have amyloid. Lecanemab is expected to receive TGA approval by the end of 2024.
Highlighted Terms
Related News
Lecanemab: the drug giving hope to people at risk of dementia | HMRI
Lecanemab, a drug trialed at HMRI, effectively removes amyloid from the brain, potentially preventing Alzheimer's and dementia. The trial involved 400 participants nationwide, with 20 found to have amyloid. Lecanemab is expected to receive TGA approval by the end of 2024.